Free Trial

Royalty Pharma (RPRX) Competitors

Royalty Pharma logo
$32.82 +0.11 (+0.34%)
As of 04:00 PM Eastern

RPRX vs. ZTS, CORT, JAZZ, PRGO, SUPN, PCRX, OMER, NKTR, ASMB, and CPIX

Should you be buying Royalty Pharma stock or one of its competitors? The main competitors of Royalty Pharma include Zoetis (ZTS), Corcept Therapeutics (CORT), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Supernus Pharmaceuticals (SUPN), Pacira BioSciences (PCRX), Omeros (OMER), Nektar Therapeutics (NKTR), Assembly Biosciences (ASMB), and Cumberland Pharmaceuticals (CPIX). These companies are all part of the "pharmaceuticals" industry.

Royalty Pharma vs.

Zoetis (NYSE:ZTS) and Royalty Pharma (NASDAQ:RPRX) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, community ranking, valuation, earnings, dividends and media sentiment.

92.8% of Zoetis shares are owned by institutional investors. Comparatively, 54.3% of Royalty Pharma shares are owned by institutional investors. 0.2% of Zoetis shares are owned by company insiders. Comparatively, 18.9% of Royalty Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Zoetis has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500. Comparatively, Royalty Pharma has a beta of 0.5, indicating that its stock price is 50% less volatile than the S&P 500.

Zoetis currently has a consensus price target of $214.40, indicating a potential upside of 36.87%. Royalty Pharma has a consensus price target of $42.50, indicating a potential upside of 29.49%. Given Zoetis' stronger consensus rating and higher possible upside, equities analysts clearly believe Zoetis is more favorable than Royalty Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zoetis
0 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
2 Strong Buy rating(s)
3.08
Royalty Pharma
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
3.00

Royalty Pharma has a net margin of 37.94% compared to Zoetis' net margin of 26.86%. Zoetis' return on equity of 53.82% beat Royalty Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Zoetis26.86% 53.82% 18.86%
Royalty Pharma 37.94%24.40%14.01%

Zoetis pays an annual dividend of $2.00 per share and has a dividend yield of 1.3%. Royalty Pharma pays an annual dividend of $0.88 per share and has a dividend yield of 2.7%. Zoetis pays out 36.6% of its earnings in the form of a dividend. Royalty Pharma pays out 60.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Zoetis has increased its dividend for 14 consecutive years.

Zoetis received 591 more outperform votes than Royalty Pharma when rated by MarketBeat users. Likewise, 77.96% of users gave Zoetis an outperform vote while only 67.99% of users gave Royalty Pharma an outperform vote.

CompanyUnderperformOutperform
ZoetisOutperform Votes
916
77.96%
Underperform Votes
259
22.04%
Royalty PharmaOutperform Votes
325
67.99%
Underperform Votes
153
32.01%

Zoetis has higher revenue and earnings than Royalty Pharma. Royalty Pharma is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zoetis$9.26B7.55$2.49B$5.4728.64
Royalty Pharma$2.26B8.36$858.98M$1.4522.63

In the previous week, Zoetis had 32 more articles in the media than Royalty Pharma. MarketBeat recorded 45 mentions for Zoetis and 13 mentions for Royalty Pharma. Royalty Pharma's average media sentiment score of 1.28 beat Zoetis' score of 1.10 indicating that Royalty Pharma is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Zoetis
32 Very Positive mention(s)
0 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Royalty Pharma
10 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Zoetis beats Royalty Pharma on 17 of the 22 factors compared between the two stocks.

Get Royalty Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for RPRX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RPRX vs. The Competition

MetricRoyalty PharmaPharmaceutical IndustryFinance SectorNASDAQ Exchange
Market Cap$18.92B$6.89B$11.13B$7.82B
Dividend Yield2.73%3.06%5.61%4.22%
P/E Ratio22.637.4422.0018.48
Price / Sales8.36242.6626.02103.91
Price / Cash7.9465.8517.6234.62
Price / Book1.836.512.664.25
Net Income$858.98M$143.21M$1.03B$248.23M
7 Day Performance3.57%3.97%1.27%3.29%
1 Month Performance4.62%0.37%-0.74%2.43%
1 Year Performance18.48%2.59%536.03%5.54%

Royalty Pharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RPRX
Royalty Pharma
4.3415 of 5 stars
$32.82
+0.3%
$42.50
+29.5%
+16.3%$18.92B$2.26B22.6380Positive News
ZTS
Zoetis
4.5117 of 5 stars
$146.85
-0.9%
$214.40
+46.0%
-2.7%$65.52B$9.26B26.8513,800Upcoming Earnings
Options Volume
Positive News
CORT
Corcept Therapeutics
4.821 of 5 stars
$62.90
+1.1%
$143.25
+127.7%
+213.4%$6.64B$675.04M49.92300Upcoming Earnings
Short Interest ↓
Positive News
JAZZ
Jazz Pharmaceuticals
4.8379 of 5 stars
$100.34
-2.4%
$187.71
+87.1%
+4.7%$6.09B$4.07B14.133,200Upcoming Earnings
Analyst Revision
News Coverage
Positive News
PRGO
Perrigo
4.8592 of 5 stars
$24.41
-3.6%
$33.00
+35.2%
-21.9%$3.33B$4.37B-20.868,900Upcoming Earnings
Dividend Announcement
Short Interest ↑
Positive News
SUPN
Supernus Pharmaceuticals
3.1437 of 5 stars
$30.29
-1.5%
$36.00
+18.9%
+6.2%$1.69B$661.82M28.31580Upcoming Earnings
PCRX
Pacira BioSciences
1.9282 of 5 stars
$25.90
+5.1%
$26.67
+3.0%
+3.6%$1.20B$700.97M-12.76720Upcoming Earnings
News Coverage
OMER
Omeros
3.8273 of 5 stars
$6.70
-1.2%
$22.50
+235.8%
+130.4%$389.03MN/A-2.90210Positive News
NKTR
Nektar Therapeutics
4.0782 of 5 stars
$0.63
-1.6%
$4.50
+619.0%
-49.3%$116.48M$98.43M-0.75220Positive News
ASMB
Assembly Biosciences
3.6992 of 5 stars
$9.94
-0.9%
$33.00
+232.0%
-10.8%$74.58M$28.52M-1.48100Upcoming Earnings
News Coverage
Positive News
CPIX
Cumberland Pharmaceuticals
0.8697 of 5 stars
$4.49
-5.7%
N/A+187.3%$62.72M$37.87M-5.8380Upcoming Earnings
Short Interest ↓
News Coverage
Positive News

Related Companies and Tools


This page (NASDAQ:RPRX) was last updated on 4/30/2025 by MarketBeat.com Staff
From Our Partners